The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Alessandro
A
Isidori
Francesco
F
Merli
Francesco
F
Angrilli
Felicetto
F
Ferrara
Francesco
F
Alesiani
Giuseppe
G
Visani
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015994:Incidence; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000139:chemically induced / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D000069283:Rituximab; D015996:Survival Rate; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D000890:Anti-Infective Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D004338:Drug Combinations; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003520:Cyclophosphamide; D011239:Prednisolone